Invea Therapeutics (INAI) investor relations material

Company overview and business model

• Focuses on developing oral, small-molecule therapies for immune-mediated inflammatory diseases (IMIDs), targeting conditions such as chronic urticaria, atopic dermatitis, prurigo nodularis, rheumatoid arthritis, IBD, asthma, and multiple sclerosis.

• Lead candidate INVA8001 is a chymase inhibitor for chronic inducible urticaria, with plans to expand to other IMIDs; INVA8003 is a preclinical ASC inhibitor targeting inflammasome-driven diseases.

• Utilizes the AlphaMeld Platform, integrating AI, ML, and generative AI for drug discovery, licensed from parent InveniAI.

• Business model includes in-licensing, AI-driven candidate identification, and potential strategic collaborations for development and commercialization.

Financial performance and metrics

• No product revenue to date; net losses of $6.3M (2024) and $2.9M (nine months ended Sept 2025); accumulated deficit of $26.8M as of Sept 30, 2025.

• Cash balance of $0.3M as of Sept 30, 2025; pro forma cash post-IPO estimated at $25.6M.

• Research and development expenses decreased due to funding constraints; general and administrative expenses increased in 2024 due to IPO-related costs.

• Auditor included a going concern paragraph due to recurring losses and capital needs.

Use of proceeds and capital allocation

• Net proceeds of ~$30.6M (or $35.5M with full over-allotment) expected, assuming $11.00/share IPO price.

• ~$15M allocated to INVA8001 Phase 2a trial and data readout; $0.3M to INVA8003 preclinical development.

• ~$3.1M to repay related party and other debt; $2.5M to settle accrued liabilities; $0.1M for AlphaMeld license fees.

• Remainder for general corporate purposes, working capital, and operating expenses.